Company: BIAF
Filing Date: 2025-06-02
Form Type: DEF 14A
Source: 0001641172-25-013280
Chunk: 1

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-02
Form: DEF 14A
Chunk 1
---
 bioAffinity Technologies, I am greatly encouraged
by the growing adoption and use by physicians of our first test, CyPath Lung, a noninvasive test for lung cancer, and
of the technological advancements that our team continues to make in its fight to address the urgent need for noninvasive, early-stage
diagnosis.

Whether or not you plan to attend the Annual Meeting,
your vote matters. We encourage you to promptly vote your shares by proxy over the internet, via telephone or by mail.

Your trust in our team and belief in our technology
are invaluable. On behalf of our Board of Directors, our executive leadership team, and our dedicated team of scientists and businesspeople,
we extend our sincerest gratitude for your continued support of and investment in bioAffinity Technologies.

| Sincerely,                            |
| Maria Zannes                          |
| President and Chief Executive Officer |

<div align='center'>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

TO BE HELD ON JULY 25, 2025</div>

Notice is hereby given that bioAffinity
Technologies, Inc. (the “Company” or “bioAffinity Technologies”) will host its annual
meeting of stockholders (the “Annual Meeting”) on Friday, July 25, 2025, at 8:00 a.m. Central Time.
The Annual Meeting will be held in person at the Company’s principal office at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas
78217. The Annual Meeting is being held for the following purposes:

| (1) | To                                                                                                                                                                                                                                                                                                                                                                                                     
 elect the seven director nominees listed in the accompanying proxy statement to serve until the next annual meeting of stockholders                                                                                                                                                                                                                                                                    
 and until their successors are duly elected and qualified;                                                                                                                                                                                                                                                                                                                                             |
| (2) | To ratify the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025;                                                                                                                                                                                                                                        |
| (3) | To                                                                                                                                                                                                                                                                                                                                                                                                     
 approve an amendment to the Company’s Certificate of Incorporation, as amended, in substantially the form attached to the accompanying                                                                                                                                                                                                                                                                 
 proxy statement as Appendix A, at the discretion of our Board of Directors (the “Board”), to effect                                                                                                                                                                                                                                                                                                    
 a reverse stock split with respect to the Company’s issued and outstanding shares of common stock, par value $0.007 per share                                                                                                                                                                                                                                                                          
 (“Common Stock”), as well as stock